(ADUS) Addus HomeCare - Overview
Stock: Personal Care, Hospice, Home Health
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 28.6% |
| Relative Tail Risk | -3.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -23.71 |
| Character TTM | |
|---|---|
| Beta | 0.449 |
| Beta Downside | -0.025 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.91% |
| CAGR/Max DD | -0.01 |
Description: ADUS Addus HomeCare January 14, 2026
Addus HomeCare Corporation (NASDAQ:ADUS) delivers non-medical personal care, hospice, and skilled home-health services to elderly, chronically ill, and disabled individuals across the United States. Its three operating segments-Personal Care, Hospice, and Home Health-serve a mix of government payors, managed-care plans, commercial insurers, and private clients, providing assistance with daily living, palliative care, and post-acute therapy respectively.
Recent public filings show ADUS generated roughly $1.3 billion in revenue for FY 2023, up about 5 % year-over-year, with an operating margin near 5 % after integrating recent acquisitions. The company’s growth is anchored by macro-drivers such as the U.S. aging population (the 65-plus cohort is projected to reach 21 % of the total population by 2030) and increasing pressure on hospitals to reduce readmissions, which fuels demand for home-based care. A key risk factor is the sensitivity of Medicaid and Medicare reimbursement rates, which historically have averaged a 2-3 % annual inflation adjustment but are subject to policy volatility.
For a deeper quantitative dive, you might explore ValueRay’s detailed financial models and scenario analyses for ADUS.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 85.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.97 > 1.0 |
| NWC/Revenue: 7.71% < 20% (prev 15.43%; Δ -7.72% < -1%) |
| CFO/TA 0.07 > 3% & CFO 103.2m > Net Income 85.7m |
| Net Debt (100.6m) to EBITDA (141.4m): 0.71 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.4m) vs 12m ago 0.60% < -2% |
| Gross Margin: 32.66% > 18% (prev 0.32%; Δ 3233 % > 0.5%) |
| Asset Turnover: 104.6% > 50% (prev 98.34%; Δ 6.21% > 0%) |
| Interest Coverage Ratio: 10.14 > 6 (EBITDA TTM 141.4m / Interest Expense TTM 12.4m) |
Altman Z'' 3.40
| A: 0.07 (Total Current Assets 260.7m - Total Current Liabilities 156.8m) / Total Assets 1.42b |
| B: 0.31 (Retained Earnings 442.6m / Total Assets 1.42b) |
| C: 0.10 (EBIT TTM 125.9m / Avg Total Assets 1.29b) |
| D: 1.19 (Book Value of Equity 442.6m / Total Liabilities 373.0m) |
| Altman-Z'' Score: 3.40 = A |
Beneish M -2.68
| DSRI: 1.16 (Receivables 134.1m/97.4m, Revenue 1.35b/1.13b) |
| GMI: 0.99 (GM 32.66% / 32.28%) |
| AQI: 1.18 (AQ_t 0.77 / AQ_t-1 0.65) |
| SGI: 1.19 (Revenue 1.35b / 1.13b) |
| TATA: -0.01 (NI 85.7m - CFO 103.2m) / TA 1.42b) |
| Beneish M-Score: -2.68 (Cap -4..+1) = A |
What is the price of ADUS shares?
Over the past week, the price has changed by +2.32%, over one month by -4.60%, over three months by -7.28% and over the past year by -11.58%.
Is ADUS a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ADUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 141 | 33.2% |
| Analysts Target Price | 141 | 33.2% |
| ValueRay Target Price | 98.9 | -6.6% |
ADUS Fundamental Data Overview February 05, 2026
P/E Forward = 15.4083
P/S = 1.4673
P/B = 1.854
P/EG = 1.0265
Revenue TTM = 1.35b USD
EBIT TTM = 125.9m USD
EBITDA TTM = 141.4m USD
Long Term Debt = 150.6m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 202.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 100.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (1.98b + Debt 202.5m - CCE 101.9m)
Interest Coverage Ratio = 10.14 (Ebit TTM 125.9m / Interest Expense TTM 12.4m)
EV/FCF = 20.85x (Enterprise Value 2.08b / FCF TTM 99.6m)
FCF Yield = 4.80% (FCF TTM 99.6m / Enterprise Value 2.08b)
FCF Margin = 7.39% (FCF TTM 99.6m / Revenue TTM 1.35b)
Net Margin = 6.36% (Net Income TTM 85.7m / Revenue TTM 1.35b)
Gross Margin = 32.66% ((Revenue TTM 1.35b - Cost of Revenue TTM 906.8m) / Revenue TTM)
Gross Margin QoQ = 32.21% (prev 32.59%)
Tobins Q-Ratio = 1.46 (Enterprise Value 2.08b / Total Assets 1.42b)
Interest Expense / Debt = 1.28% (Interest Expense 2.58m / Debt 202.5m)
Taxrate = 24.73% (7.51m / 30.4m)
NOPAT = 94.8m (EBIT 125.9m * (1 - 24.73%))
Current Ratio = 1.66 (Total Current Assets 260.7m / Total Current Liabilities 156.8m)
Debt / Equity = 0.19 (Debt 202.5m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 0.71 (Net Debt 100.6m / EBITDA 141.4m)
Debt / FCF = 1.01 (Net Debt 100.6m / FCF TTM 99.6m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.65% (Net Income 85.7m / Total Assets 1.42b)
RoE = 8.49% (Net Income TTM 85.7m / Total Stockholder Equity 1.01b)
RoCE = 10.85% (EBIT 125.9m / Capital Employed (Equity 1.01b + L.T.Debt 150.6m))
RoIC = 7.94% (NOPAT 94.8m / Invested Capital 1.19b)
WACC = 6.96% (E(1.98b)/V(2.18b) * Re(7.57%) + D(202.5m)/V(2.18b) * Rd(1.28%) * (1-Tc(0.25)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.12%
[DCF Debug] Terminal Value 82.68% ; FCFF base≈110.3m ; Y1≈116.0m ; Y5≈135.7m
Fair Price DCF = 155.6 (EV 2.98b - Net Debt 100.6m = Equity 2.88b / Shares 18.5m; r=6.96% [WACC]; 5y FCF grow 5.59% → 2.90% )
EPS Correlation: -0.32 | EPS CAGR: -41.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.90 | Revenue CAGR: 13.59% | SUE: 3.17 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.58 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=6.86 | Chg30d=+0.012 | Revisions Net=+1 | Growth EPS=+11.2% | Growth Revenue=+7.2%